Nomination Committee appointed for the 2019 Annual General Meeting in PledPharma
October 26, 2018
The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on May 7 2019. The Nomination Committee is composed of members appointed by the four largest shareholders in terms of voting rights, that have accepted the invitation to participate in the committee.
The following members have been appointed by the following shareholders:
Nortal Investments AB and Zimbrine Holding BV: Staffan Persson
Berinor BV: Peter Lindell
Flerie Participation AB: Carl-Johan Spak
Handelsbanken Fonder: Astrid Samuelsson
In total, the Nomination Committee represents ca 38 % of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Peter Lindell, Carl-Johan Spak and Astrid Samuelsson are also independent in relation to Nortal Investments AB and Zimbrine Holding BV, which is the largest group of shareholders in the company in terms of votes.
The Nomination Committee has elected Staffan Persson as chairman. Håkan Åström (Chairman of PledPharma) has been co-opted to the Nomination Committee.
The Committee’s assignment is to present to the Annual General Meeting proposals regarding Chairman and other members of the board as well as remuneration to the Board´s members. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2020.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email: firstname.lastname@example.org
For more information, please contact:
Håkan Åström, Chairman, phone: +4670 374 72 13
Yilmaz Mahshid, CFO, phone: +4672 231 68 00
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and serves as the basis for the initiated global phase III program. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. A proof of principle study has been conducted and will serve as the basis for the continued development. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see https://www.egetis.com/